Literature DB >> 25523760

Cell cycle status of CD34(+) hemopoietic stem cells determines lentiviral integration in actively transcribed and development-related genes.

Eleni Papanikolaou1, Anna Paruzynski2, Ioannis Kasampalidis3, Annette Deichmann2, Evangelos Stamateris4, Manfred Schmidt2, Christof von Kalle2, Nicholas P Anagnou1.   

Abstract

Gene therapy utilizing lentiviral-vectors (LVs) is postulated as a dynamic therapeutic alternative for monogenic diseases. However, retroviral gene transfer may cause insertional mutagenesis. Although, such risks had been originally estimated as extremely low, several reports of leukemias or clonal dominance, have led to a re-evaluation of the mechanisms operating in insertional mutagenesis. Therefore, unraveling the mechanism of retroviral integration is mandatory toward safer gene therapy applications. In the present study, we undertook an experimental approach which enabled direct correlation of the cell cycle stage of the target cell with the integration profile of LVs. CD34(+) cells arrested at different stages of cell cycle, were transduced with a GFP-LV. LAM-PCR was employed for integration site detection, followed by microarray analysis to correlate transcribed genes with integration sites. The results indicate that ~10% of integration events occurred in actively transcribed genes and that the cell cycle stage of target cells affects integration pattern. Specifically, use of thymine promoted a safer profile, since it significantly reduced integration within cell cycle-related genes, while we observed increased possibility for integration into genes related to development, and decreased possibility for integration within cell cycle and cancer-related genes, when transduction occurs during mitosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25523760      PMCID: PMC4395775          DOI: 10.1038/mt.2014.246

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  39 in total

1.  HIV-1 integration in the human genome favors active genes and local hotspots.

Authors:  Astrid R W Schröder; Paul Shinn; Huaming Chen; Charles Berry; Joseph R Ecker; Frederic Bushman
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

2.  Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR.

Authors:  Fabrizia Urbinati; Paritha Arumugam; Tomoyasu Higashimoto; Anil Perumbeti; Kyle Mitts; Ping Xia; Punam Malik
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

Review 3.  Lentiviruses as gene transfer agents for delivery to non-dividing cells.

Authors:  L Naldini
Journal:  Curr Opin Biotechnol       Date:  1998-10       Impact factor: 9.740

4.  Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate.

Authors:  J G Julias; V K Pathak
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

5.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

6.  Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription.

Authors:  M K Lewinski; D Bisgrove; P Shinn; H Chen; C Hoffmann; S Hannenhalli; E Verdin; C C Berry; J R Ecker; F D Bushman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  A model for predicting the risk of cancer consequent to retroviral gene therapy.

Authors:  F L Moolten; L A Cupples
Journal:  Hum Gene Ther       Date:  1992-10       Impact factor: 5.695

8.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

9.  Hot spots of retroviral integration in human CD34+ hematopoietic cells.

Authors:  Claudia Cattoglio; Giulia Facchini; Daniela Sartori; Antonella Antonelli; Annarita Miccio; Barbara Cassani; Manfred Schmidt; Christof von Kalle; Steve Howe; Adrian J Thrasher; Alessandro Aiuti; Giuliana Ferrari; Alessandra Recchia; Fulvio Mavilio
Journal:  Blood       Date:  2007-05-16       Impact factor: 22.113

10.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Maurilio Ponzoni; Cynthia Bartholomae; Lucia Sergi Sergi; Fabrizio Benedicenti; Alessandro Ambrosi; Clelia Di Serio; Claudio Doglioni; Christof von Kalle; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2006-05-28       Impact factor: 54.908

View more
  3 in total

1.  Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent.

Authors:  Camille Lévy; Fouzia Amirache; Anais Girard-Gagnepain; Cecilia Frecha; Francisco J Roman-Rodríguez; Ornellie Bernadin; Caroline Costa; Didier Nègre; Alejandra Gutierrez-Guerrero; Lenard S Vranckx; Isabelle Clerc; Naomi Taylor; Lars Thielecke; Kerstin Cornils; Juan A Bueren; Paula Rio; Rik Gijsbers; François-Loïc Cosset; Els Verhoeyen
Journal:  Blood Adv       Date:  2017-10-24

2.  Prolonged Integration Site Selection of a Lentiviral Vector in the Genome of Human Keratinocytes.

Authors:  Wei Qian; Yong Wang; Rui-Fu Li; Xin Zhou; Jing Liu; Dai-Zhi Peng
Journal:  Med Sci Monit       Date:  2017-03-03

3.  In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions.

Authors:  Clara T Nicolas; Caitlin J VanLith; Raymond D Hickey; Zeji Du; Lori G Hillin; Rebekah M Guthman; William J Cao; Benjamin Haugo; Annika Lillegard; Diya Roy; Aditya Bhagwate; Daniel O'Brien; Jean-Pierre Kocher; Robert A Kaiser; Stephen J Russell; Joseph B Lillegard
Journal:  Nat Commun       Date:  2022-08-25       Impact factor: 17.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.